StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Organic / Comparable Sales Growth (%) (%)

Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A

QuarterlyAnnual
Latest, Q3 2026
5.7%
Period ended Sep 30, 2026
Change on a year earlier
+1.0 pts
4.7% in Q3 2025
History
43 quarters
Since Q4 2015
Sources
43
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Organic / Comparable Sales Growth (%) (%)Year on yearSource
Q3 2026Sep 30, 20265.7%+1.0 ptsSEC Filing (0001628280-26-066601) ↗
Q2 2026Jun 30, 20265.1%+1.6 ptsSEC Filing (0001628280-26-048377) ↗
Q1 2026Mar 31, 20264.9%-0.8 ptsSEC Filing (0001628280-26-025365) ↗
Q4 2025Dec 31, 20256.5%-0.3 ptsSEC Filing (0001628280-26-002982) ↗
Q3 2025Sep 30, 20254.7%-0.2 ptsSEC Filing (0001628280-25-045049) ↗
Q2 2025Jun 30, 20253.5%+2.3 ptsSEC Filing (0001628280-25-035135) ↗
Q1 2025Mar 31, 20255.7%-0.1 ptsSEC Filing (0001628280-25-017924) ↗
Q4 2024Dec 31, 20246.8%+2.3 ptsSEC Filing (0001628280-25-002092) ↗
Q3 2024Sep 30, 20244.9%+2.1 ptsSEC Filing (0001628280-24-042893) ↗
Q2 2024Jun 30, 20241.2%-3.8 ptsSEC Filing (0001628280-24-032182) ↗
Q1 2024Mar 31, 20245.8%–SEC Filing (0001628280-24-016497) ↗
Q4 2023Dec 31, 20234.5%+8.0 ptsSEC Filing (0001628280-24-002009) ↗
Q3 2023Sep 30, 20232.8%+2.4 ptsSEC Filing (0001628280-23-034544) ↗
Q2 2023Jun 30, 20235.0%+6.6 ptsSEC Filing (0001628280-23-025156) ↗
Q4 2022Dec 31, 2022-3.5%-16.7 ptsSEC Filing (0001628280-23-001516) ↗
Q3 2022Sep 30, 20220.4%-0.5 ptsSEC Filing (0001628280-22-026588) ↗

Cite this data

StockData. (2026). Abbott Laboratories Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Organic / Comparable Sales Growth (%) (%), quarterly Q4 2015–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-vasc-yoy-org

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.